WebNEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is … WebApr 6, 2024 · Intra-Cellular Therapies Inc’s price is currently up 9.51% so far this month. During the month of April, Intra-Cellular Therapies Inc’s stock price has reached a high of $59.43 and a low of $53.52. Over the last year, Intra-Cellular Therapies Inc has hit prices as high as $66.00 and as low as $42.01.

Why Intra-Cellular Therapies Inc’s (ITCI) Stock Is Up 4.94%

WebApr 11, 2024 · The Intra-Cellular Therapies Inc. stock price fell by -0.626% on the last day (Tuesday, 11th Apr 2024) from $59.07 to $58.70.During the last trading day the stock … WebStock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. take everything after a character in excel

Intra-Cellular Therapies Reports Second Quarter 2024 Financial …

WebMar 1, 2024 · Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous … WebSenior Neuroscience Sales Specialist at Intra-Cellular Therapies St Louis, Missouri, United States. 755 followers 500+ connections. Join to view … WebApr 2, 2024 · Sharon Mates, PhD. Intra-Cellular Therapies recently announced the expansion of its central nervous system (CNS) pipeline with ITI-1284 ODT-SL, with plans to develop the agent for the treatment of dementia-related psychosis and the treatment of certain depressive disorders in elderly patients. 1. ITI-1284 ODT-SL is formulated as an … take everything